Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Dissecting Aneurysm in Cervical Artery Dissection: Insights From the STOP-CAD Study
Khan, Muhib, Keser, Z, Shu, Liqi , Lee, Elizabeth M., Ho, Melanie, Klein, Piers, Mallick, Dania, Griffin, Kim, Mandel, Daniel M, Leker, Ronen R., Metanis, Issa, Krishnaiah, Balaji , Omran, Setareh Salehi , Bakradze, Ekaterina, Henninger, Nils, Engelter, Stefan T, Antonenko, Kateryna, Marto, Joao Pedro, Rothstein, Aaron, Khazaal, Ossama , Nolte, Christian H., Crandall, Ross Curtiss, Lester, Evan, Nehme, Ahmad , Ghannam, Malik, AlMajali, Mohammad, Elnazeir, Marwa , Kasab, Sami Al, Asad, Syed Daniyal , Balabhadra, Anvesh , Fonseca, Ana Catarina , Cruz, Diana , Romoli, Michele, Sen, Shayak, Zedde, Marialuisa, Samaniego, Edgar A., Zubair, Adeel , Stretz, Christoph, Kam, Wayneho , AbdalKader, Mohamad, Yaghi, Shadi, Nguyen, Thanh N., Keser, Zafer , Klein, Piers , Henninger, Nils , Mandel, Daniel , Lee, Elizabeth , Nolte, Christian H. , Khan, Muhib , Keser, Zafer , Lee, Elizabeth , Klein, Piers , Griffin, Kim J. , Mandel, Daniel M , Leker, Ronen R , Metanis, Issa , Salehi Omran, Setareh , Bakradze, Ekaterina , Henninger, Nils , Engelter, Stefan T , Heldner, Mirjam R , Antonenko, Kateryna , Siegler, James E , Marto, João Pedro , Rothstein, Aaron , Khazaal, Ossama , Nolte, Christian H , Crandall, Ross , Nehme, Ahmad , Mac Grory, Brian , Ghannam, Malik , Almajali, Mohammad , Elnazeir, Marwa , Al Kasab, Sami , Asad, Syed Daniyal , Balabhadra, Anvesh , Fonseca, Ana Catarina , Cruz, Diana , Romoli, Michele , Saleh Velez, Faddi , Simpkins, Alexis N , Zedde, Marialuisa , Samaniego, Edgar A , Zubair, Adeel , Stretz, Christoph , Kam, Wayneho , Abdalkader, Mohamad , Yaghi, Shadi , Nguyen, Thanh N , Khan, Muhib , Ho, Melanie, Metanis, Issa , Shahripour, Reza Bavarsad , Bakradze, Ekaterina , Engelter, Stefan T. , Heldner, Mirjam R. , Siegler, James E. , Marto, João Pedro , Rothstein, Aaron , Crandall, Ross , Grory, Brian Mac , Ghannam, Malik , Kasab, Sami Al , Velez, Faddi G. Saleh , Simpkins, Alexis N. , Zedde, Marialuisa , Stretz, Christoph , Abdalkader, Mohamad , Yaghi, Shadi

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: 4 | Pages: 865-875

10.1161/strokeaha.125.054847 | PMID 41608793 Get It

BACKGROUND: Cervical artery dissection (CeAD) may result in dissecting aneurysm (DA) formation. We aimed to characterize risk factors and clinical outcomes associated with DA in a large, international CeAD cohort. METHODS: We performed a secondary analysis of STOP-CAD (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection), an international, multicenter, retrospective cohort. Patients with spontaneous CeAD were assessed for DA at baseline and de novo DA formation. Significant covariates in univariable analysis were included in multivariable regression models aiming to identify factors associated with DA formation. Logistic regression and Cox proportional hazards models evaluated the association of DA with ischemic and hemorrhagic outcomes. RESULTS: Among 4008 patients with CeAD, 546 (13.6%) had a DA at baseline, and 221/2938 (7.5%) patients developed a de novo DA during follow-up, of which 172/221 (78.2%) were detected in the first 180 days. Patients with DA had a mean age of 47 years, and 383 (49.9%) were women. Baseline or de novo DA was associated with a history of connective tissue disorder (adjusted odds ratio [aOR], 2.02 [95% CI, 1.22–3.36]), fibromuscular dysplasia (aOR, 1.69 [95% CI, 1.28–2.25]), and multiple vessel dissection (aOR, 1.53 [95% CI, 1.19–1.98]). Lower odds of DA were seen in Hispanic ethnicity (aOR, 0.64 [95% CI, 0.43–0.97]) and ischemic stroke presentation (aOR, 0.41 [95% CI, 0.34–0.49]). Fibromuscular dysplasia was associated with de novo DA formation (aOR, 2.30 [95% CI, 1.52–3.49]). DA was not associated with ischemic stroke (hazard ratio, 0.71 [95% CI, 0.44–1.16]; P =0.173) or intracranial hemorrhage (HR, 1.09 [95% CI, 0.42–2.84]; P =0.86) by day 180. CONCLUSIONS: DAs are relatively common manifestations of CeAD, typically occurring within 6 months of CeAD diagnosis. DA was not associated with an increased risk of subsequent ischemic stroke or intracranial hemorrhage.
“By the Skin of Our Teeth”: U.S. Hospital, Regional, and State Experiences of Scarcity During the COVID ‐19 Pandemic
Ennis, Jackson S. , Nguyen, Nicholas V. , Smith, Alexander K., Kramer, Daniel B. , Dp, Sulmasy, Tilburt, Jon C. , DeMartino, Erin S. , Smith, Alexander K. , Riggan, Kirsten A. , Nguyen, N.V. , Sulmasy, Daniel P.

Mayo Clinic

Journal of the American Geriatrics Society | January 20, 2026 | Volume: 74 | Issue: 3 | Pages: 729-737

10.1111/jgs.70300 | PMID 41556783 Get It

ABSTRACT Background The COVID‐19 pandemic presented unprecedented challenges to hospital system and critical care resources, leading to significant changes to operations and patient care. There are limited national data on these changes and instances of unsanctioned deviations from patient care, yet understanding the COVID response is key to future preparedness efforts. We sought to understand how hospitals and states navigated scarcity during COVID‐19, particularly in the absence of a declaration of crisis standards of care. Methods Between February 2022 and September 2022 we conducted 34 interviews with 36 leaders of U.S. states' COVID‐19 planning and response efforts. Interviews were transcribed verbatim and verified. We analyzed interviews using iterative inductive thematic analysis for descriptions of resource scarcity and changes to policies and procedures to prevent rationing lifesaving care. Results Nearly all participants described equipment and personnel scarcity in their home institution or state during COVID‐19. Hospitals across regions and states developed formal and informal coordination processes for load and resource sharing in response to influxes of high‐acuity patients, avoiding formal rationing of lifesaving resources in many regions. Participants also described unsanctioned patient triage, early discharge, and patients counseled to accept less aggressive care (e.g., premature transition to hospice) in states that had not declared crisis standards of care. Conclusions Extending limited resources and inter‐institutional collaboration helped avoid formal rationing. Yet, patient care was unquestionably impacted due to scarcity, both real and perceived. Reports of using hospital triage protocols to deny patients lifesaving care outside of formally recognized crisis conditions and attempts to nudge patients to accept less‐resource‐intensive care are concerning. This may have had disproportionate effects on older adults, individuals with disabilities, and racial and ethnic minoritized groups. To avoid unsanctioned deviations from standard practice in future health emergencies, we recommend that transparent and equitable triage protocols are implemented with robust oversight.
Intracranial mesenchymal tumor, FET::CREB fusion-positive: An integrative analysis of 81 cases
Rajan, Sharika, Chung, Hye‐Jung, Wu, Zhichao , Dazelle, Karen , Abdullaev, Zied , Tyagi, Manoj, Ferrone, Christina K. , Raffeld, Mark , Lee, Ina, Chen, Jie , Cathcart, Sahara , Giannini, C., Nguyen, Aivi, Gökden, Murat , Perry, A., Fernandes, Igor Lima , Putnam, Angelica R. , Kurek, Kyle C., Green, Richard M, Lucas, Calixto-Hope, González-Gómez, Ignacio, Lopez, G., Ra, Prayson, Yeaney, Gabrielle , Dermawan, Josephine Kam Tai, Chkheidze, Rati , Appin, Christina , Uhlmann, Erik J. , Taliansky, A , Blessing, Melissa M. , Mohila, Carrie, Deisch, Jeremy , Andreiuolo, Felipe, Crawford, John R, Stemmer‐Rachamimov, Anat , Lakis, Nelli S., Re, Schmidt, Chacko, Geeta, Newbury, Robert, Neill, Stewart G. , Morales, Bryan , Fecher, Roger , Sloan, Emily A. , Solomon, David A, Nasrallah, MacLean, Quezado, Martha, Aldape, Kenneth, Solomon, David A. , Chen, Jie , Giannini, Caterina , Perry, Arie , Chkheidze, Rati , Deisch, Jeremy , Solomon, David A , Aldape, Kenneth , Jones, Karra A , López, Giselle Y. , Wu, Zhichao, Singh, Omkar, Gagan, Jeffrey , Nguyen, Aivi, Perry, Arie , Green, Richard M., Eberhart, Charles G. , Lucas, Calixto-Hope C. , Jones, Karra A. , Mohila, Carrie , Cotter, Jennifer A. , Andreiuolo, Felipe , Crawford, John R, Mount, Christopher , Lakis, Nelli S., Schmidt, Robert, Chacko, Geeta , Nasrallah, MacLean P. , Quezado, Martha , Fonseca, Adriana

Mayo Clinic

Neuro-Oncology | January 17, 2026 | Volume: 28 | Issue: 4 | Pages: 939-951

10.1093/neuonc/noag001 | PMID 41569358 Get It

Abstract Background Intracranial mesenchymal tumors, FET::CREB fusion-positive (ICMT), show fusions involving FET RNA-binding protein family genes (EWSR1 or FUS) and CREB family of transcription factors (ATF1, CREB1, or CREM). The methylation signature(s), gene expression characteristics, and clinical behavior of this important tumor type require further characterization. Methods We study the methylation profiles of 81 ICMT cases (61 newly profiled cases and 20 cases from publicly available sources). Clinicopathologic and genomic data were recorded for each case when available. Results ICMT showed a relatively distinct methylation signature compared to related tumors. Among the 65 cases where fusion types were documented, the identified fusions included EWSR1::ATF1 (25 cases), EWSR1::CREB1 (12 cases), EWSR1::CREM (21 cases), FUS::CREM (3 cases), and SMARCA2::CREM (4 cases). We confirmed the prior description of 2 distinct subgroups of ICMT (subclasses A and B). The majority of the cases belonged to subclass A (n = 69; 85%), which showed a higher median age compared to subclass B patients (26 years vs. 15 years). Subclass B cases (n = 12; 15%) showed shorter progression-free survival (P < 0.01). Gene expression analysis of ICMT showed key overexpressed markers in ICMT, with significant CREM overexpression regardless of fusion type, when compared to either meningioma alone or a larger group of CNS tumors. Conclusions This work provides further characterization of ICMT as an important CNS mesenchymal neoplasm that is prone to tumor recurrence, showing 2 prognostically relevant methylation subclasses and warranting diagnostic distinction from other epigenetically and histologically related tumors. ICMTs show substantial overexpression of the CREM gene, independent of fusion type.
The North American Prodromal Synucleinopathy study: protocol for a multi-site, longitudinal, observational study of idiopathic/isolated rapid eye movement sleep behavior disorder
Lim, Miranda, Neilson, Lee E. , Dang, Bianca H. , Locke, Jessica , Cunningham, Hannah, Brewer, Jessica V., Pelletier, Amélie , Miyagawa, Toji , Davis, Albert A. , McLeland, Jennifer S, Criswell, Susan R. , Howell, Michael J., Schenck, Carlos H, Bliwise, Donald L, Miglis, Mitchell G. , Sum-Ping, Oliver, LEE-IANNOTTI, JOYCE, Shprecher, David R, Campbell, M. C., Fields, Julie A. , Gagnon, Jean-François, Kotzbauer, Paul, Gan-Or, Ziv, Ross, Owen A, Kantarci, Kejal, Lowe, VJ, Hu, Xiaoping , Martens, Kaylena A Ehgoetz, Hu, M, Xiong, Chengjie, Postuma, Ronald B, Boeve, Bradley F, Ju, Yo‐El S. , Zangrilli, Maggie, Kraft, Ruth, Tucker, Kelsey, Landsell, Amanda, Butler, Gareth, Blake, Tyler, Wang, Amy J. , Lavadia, Loren, Orford, Jessica, Otterbein, Abigail, Gamache, David E., Rivera, Adreanne, Siegler, Jordan, Nguyen, Vince, Machnik, Jannika , Viviani, Adele M.L., Powers, Katherine, Keil, Alison, Ligman, Brittany R. , Olivo, Cosette, Bryant-Ekstrand, Mohini, Hansen, A. G., Ekis, Arlynn E., Nagum, Ryn, Bates, Leland, Schroeder, Carly, Bryants, Marina, Bauman, Jessica, Arik, Anam J., Gan‐Or, Ziv , Howell, Michael J. , Sum‐Ping, Oliver , Lim, Miranda M , Elliott, Jonathan E , Cunningham, Hannah , St Louis, E K , Criswell, Susan R , Schenck, Carlos H , Avidan, Alon Y , Trotti, Lynn Marie , Bliwise, Donald L , Huddleston, Daniel E , Miglis, Mitchell G , Duff, Kevin , Singer, Wolfgang , Gan-Or, Ziv , Ross, Owen A , Kantarci, Kejal , Hu, Michele T M , Boeve, Brad , Howell, Michael J , Neilson, Lee E , Sum-Ping, Oliver , Elliott, Jonathan E. , Locke, Jessica R, Dennis, Laura E. , Dovek, Laura , Louis, Erik K. St. , McCarter, Stuart J. , McLeland, Jennifer , Howell, Michael J, Schenck, Carlos H. , Avidan, Alon Y. , Trotti, Lynn Marie , Bliwise, Donald L. , Huddleston, Daniel E. , Videnovic, Aleksandar , Lee‐Iannotti, Joyce , Shprecher, David , Duff, Kevin , Ferman, Tanis J. , Campbell, Meghan C., Kotzbauer, Paul T. , Ross, Owen A. , Kantarci, Kejal , Martens, Kaylena Ehgoetz, Xiong, Chengjie , Postuma, Ronald B. , Boeve, Bradley F. , Heath, Brianna E. , Powers, Katherine , Bryant‐Ekstrand, Mohini , Hansen, Abigail

Mayo Clinic

SLEEP Advances | January 17, 2026 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/sleepadvances/zpag007 | PMID 41725984 Get It

Abstract Isolated/idiopathic rapid eye movement sleep behavior disorder (iRBD) is a usually prodromal manifestation of neurodegenerative disorders with α-synuclein pathology: Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Clinical trials in the iRBD population face substantial barriers: limited access to well-characterized cohorts, inconsistent assessment protocols across centers, and the absence of validated biomarkers of disease burden. The North American Prodromal Synucleinopathy (NAPS) Consortium was established to address these challenges and facilitate clinical trials for neuroprotective therapies targeting synucleinopathy at the earliest known stages. In this multi-site, longitudinal, observational study, nine academic centers across North America will enroll and follow over 500 individuals with iRBD from existing sleep centers. Sixty control participants, matched for age, sex, and race will also be recruited. A harmonized protocol—including a standardized clinical battery assessing motor, cognitive, autonomic, psychiatric, sensory, and sleep function; structured diagnostic adjudication; biospecimen collection; and centralized analysis of both polysomnography and neuroimaging data—is outlined herein and reflects NAPS Stage 2. Each participants completes these assessments annually, and are replaced in the event of phenoconversion. By unifying assessments and expanding geographic reach, NAPS lays the groundwork for efficient, well-powered clinical trials designed to delay or prevent progression of iRBD to overt PD, DLB, or MSA—ultimately enabling earlier, more effective therapeutic intervention for neurodegenerative disease. Registered at clinicaltrials.gov (NCT05826457).
Practical Interpretation of Bone Scintigraphy: Metastases, Fractures, and Beyond
Haug, Logan P. , Brown, Parker J. , Bishay, Steven , Lombardi, Alecio F. , Huang, Steve S. , Shin, Clifford , Koran, Mary Ellen I. , Long, J. B., Martínez, Felipe Derteano, Nguyen, Ba D. , Long, Jeremiah R. , Bishay, Steven E , Long, Jeremiah , Martinez, Felipe , Nguyen, B D , Koran, Mary Ellen

Mayo Clinic

RadioGraphics | January 15, 2026 | Volume: 46 | Issue: 2 | Pages: No page available

10.1148/rg.250055 | PMID 41538361 Get It

Bone scintigraphy is a valuable adjunct to cross-sectional imaging and can be used to evaluate disease extent in multifocal processes such as blastic osseous metastatic disease, provide diagnostic information to aid in problem solving in challenging cases, and serve as the primary diagnostic modality for diseases that manifest with pathognomonic scintigraphic appearances.
Impact of infusion timing (IT) on survival outcomes across gastrointestinal (GI) malignancies: A multicenter analysis of circadian rhythm (CR) effects on immune checkpoint inhibitor (ICI) activity.
Youssef, Amal M. , Alsulaiman, Abdullah, Pirozzi, Angelo , Ahn, Daniel H., Yoon, Harry H. , Starr, Jason S., Zhu, Mojun, O'Donnell, C., Jin, Zhaohu, Tran, Nguyen H., Fonkoua, Lionel Aurelien Kankeu, Bekaii-Saab, Tanios S., Jamal, Fares , Youssef, Amal, Alsulaiman, Abdullah , Abidoye, Oluseyi , Ahn, Daniel H. , Starr, Jason S. , McWilliams, Robert R. , Pedersen, Katrina S. , Xie, Hao , Hálfdánarson, Þorvarður R. , Tran, Nguyen H. , Fonkoua, Lionel Aurelien Kankeu , Borad, Mitesh J. , Bekaii‐Saab, Tanios , Sonbol, Mohamad Bassam

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 837-837

10.1200/jco.2026.44.2_suppl.837 Get It

837 Background: A recent randomized trial suggested that CR may influence ICI activity in patients with lung cancer. However, the same has not been established in GI cancers, where reports have shown mixed results with variable definitions of 'early' vs 'late' IT. We evaluated multiple approaches to assess the impact of CR on first-line ICI in GI malignancies. Methods: This retrospective study included patients from three Mayo Clinic sites (N=455). Both previously reported IT cutoffs and a new cutoff derived from ROC analysis were evaluated. Patients were categorized by the median of all ITs, the median of the first four ITs, and whether ≥20% of ITs occurred before the identified cutoff. Univariate and multivariate Cox regression (adjusting for age, MSI status, type of cancer, metastasis status, number of cycles, and receipt of chemotherapy with ICI) assessed associations with OS. KM analyses were performed to illustrate survival differences. The primary endpoint was OS. Results: When patients were categorized based on whether ≥20% of infusions occurred before 14:00 (ROC-derived cutoff), a significant association with OS was observed. On univariate analysis, early infusion timing was associated with improved survival (HR 2.30, 95% CI 1.58–3.32, p <0.001). This remained significant after multivariable adjustment (HR 2.11, 95% CI 1.41–3.16, p < 0.001). Median OS was 14.2 months in the early group vs 3.8 months in the late group (log-rank p < 0.001). Using previously defined cutoffs, categorization by the median IT of all infusions or the median of the first four infusions did not demonstrate a significant association with OS in either univariate or multivariate Cox regression analyses. Conclusions: These findings highlight the potential role of infusion timing as a chronotherapy factor in GI cancers. Given the retrospective design and heterogeneous population, prospective studies are warranted to validate this signal and clarify its clinical relevance. Baseline demographics of patients by infusion timing (early vs late). Variables Early N=412 (%) LateN=43(%) Total N=455(%) p-value Age <70 249(60.4) 21(48.8) 270 (59.3) 0.1 >70 163(39.6) 22(51.2) 185 (40.7) Gender F 118(28.6) 16(37.2) 134 (29.5) 0.3 M 294(71.4) 27(62.8) 321 (70.5) Cancer Type Gastroesophageal 109 (26.5) 8 (18.6) 117 (25.7) 0.1 Hepatocellular 159 (38.6) 24 (55.8) 183 (40.2) Biliary 86 (20.9) 4 (9.3) 90 (19.8) MSI-H 58 (14.1) 7 (16.3) 65 (14.3) Metastasis No 150 (36.4) 22 (51.2) 172 (37.8) 0.1 Yes 262 (63.6) 21 (48.8) 283 (62.2) Immunotherapy Cycle Number <6 189 (45.9) 33 (76.7) 222 (48.8) <0.001 >6 223 (54.1) 10 (23.3) 233 (51.2)
Clinico-genomic characterization of TP53 / CDKN2A co-alteration and its prognostic value in biliary tract cancer (BTC).
Pirozzi, Angelo , Teixeira, Maria Fernanda Botelho, Hoyek, Celine , Okano, Naohiro, Fonkoua, Lionel Aurelien Kankeu, Babiker, Hani M., Imai, Mitsuho , Morizane, Chigusa , Bando, Hideaki, Fujisawa, Takao , Tran, Nguyen H., Nakamura, Y., Yoshino, Takayuki, Rimassa, Lorenza, Ikeda, Masafumi, Bekaii-Saab, Tanios S., Shibuki, Taro , Teixeira, Maria Fernanda Botelho, Okano, Naohiro , Fonkoua, Lionel Aurelien Kankeu , Babiker, Hani M. , Bando, Hideaki , Majeed, Umair , Tran, Nguyen H. , Yoshino, Takayuki , Rimassa, Lorenza , Usón, Pedro Luiz Serrano , Borad, Mitesh J. , Ikeda, Masafumi , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 593-593

10.1200/jco.2026.44.2_suppl.593 Get It

593 Background: TP53 and CDKN2A are the most frequently mutated tumor suppressors in BTC, each linked to poor outcomes. Their co-alteration remains unexplored due to the current single-gene classification. Methods: This is an international multicenter study involving 35 institutions across 3 continents (North America, Asia, South America). Genomic profiling was performed on tissue or blood samples using NGS. Patients (pts) were categorized as wild-type (wt) TP53/ wt CDKN2A (WT/WT) (42%), mutated (mut) TP53 /wt CDKN2A (45%), wt TP53 /mut CDKN2A (5%), mut TP53 /mut CDKN2A (8%). Associations between TP53 / CDKN2A status , clinical and genomic features were evaluated using Chi-squared/Kruskal-Wallis tests adjusted for multiple comparisons. Overall survival (OS) from start of first-line systemic therapy was analyzed by Kaplan–Meier and multivariate Cox regression (covariates: age, sex, stage, primary site, first-line treatment, TP53/CDKN2A status), p or q<0.05. Results: We included 1079 pts with BTC. Median age 66 years with intrahepatic BTC (46%), gallbladder cancer (25%), extrahepatic BTC (22%), undefined (6%), ampullary cancer (< 1%). Most had de novo metastatic disease (54%), followed by recurrent (38%) and locally advanced disease (8%). Treatment regimens included chemotherapy (87%), chemo-immunotherapy (12%) and immunotherapy alone (<1%). The most frequently actionable genes were HER2 (8%), IDH1 (7%), BRAF (6%), FGFR2 fusions (4%), MSI-High (H) (3%). HER2 alterations were prevalent in mut TP53 /wt CDKN2A vs WT/WT (11 vs 4%, q = 0.002). IDH1 alterations were more frequent in WT/WT vs TP53 mut/wt CDKN2A (10 vs 4%, q < 0.001). FGFR2 fusions were more common in wt TP53 /mut CDKN2A vs WT/WT (17 vs 6%, q < 0.001), mut TP53 /mut CDKN2A (17 vs 3%, q = 0.001) and mut TP53 /wt CDKN2A (17 vs 1%, q < 0.001). MSI-H was enriched in mut TP53 /mut CDKN2A vs wt TP53 /mut CDKN2A (11 vs 2%, q = 0.035), mut TP53 /wt CDKN2A (11 vs 3%, q = 0.002) and WT/WT (11 vs 2%, q < 0.001). TMB-H was more prevalent in mut TP53 /mut CDKN2A vs mut TP53 /wt CDKN2A (16 vs 8%, q < 0.001) and WT/WT (16 vs 3%, q < 0.024). There was no significant difference in ORR, DCR and PFS among the four groups. mut TP53 /mut CDKN2A had the shortest median OS, while WT/WT had the longest (Table). Only 14% of mut TP53 /mut CDKN2A received regimens including immunotherapy. Conclusions: mut TP53 /mut CDKN2A represents a high-risk subset enriched with MSI-H and TMB-H pts, underscoring the need to prioritize the development of immunotherapy strategies. TP53 / CDKN2A status is prognostic, stratifying patients into distinct survival groups and supporting NGS use in the first-line setting. mOS (months) (95% CI) HR (95% CI) P-value WT/WT 21.4 (19.0-24.4) reference wt TP53 /mut CDKN2A 17.3 (12.4-25.9) 1.16 (0.79-1.71) 0.442 mut TP53 /wt CDKN2A 17.4 (16.0-19.2) 1.21 (1.01-1.45) 0.040 mut TP53 /mut CDKN2A 13.8 (11.5-18.1) 1.54 (1.13-2.09) <0.001
Multi-institutional retrospective study of IDH2-mutated cholangiocarcinoma.
Sahai, Vaibhav , Tran, Nguyen H., Griffith, Kent A. , Peterson, Nicole, Mahipal, A., King, Gentry Teng , Sahai, Vaibhav , Tran, Nguyen H. , Mahipal, Amit

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 567-567

10.1200/jco.2026.44.2_suppl.567 Get It

567 Background: IDH2 mutation is rare (1%) in patients (pts) with cholangiocarcinoma and there are no data on prognosis in these pts and response to first line (1L) chemotherapy or off-label IDH2 inhibitor enasidenib. Methods: This IRB approved retrospective study included consecutive pts 18 years or older with IDH2 mutated biliary cancer identified between 2010-2024 at 4 large academic centers. Pt characteristics, systemic therapy(ies), next-generation sequencing (NGS) and survival data were obtained via review of electronic medical records. Survival probabilities were estimated using the product-limit method of Kaplan-Meier using SAS (v9.4, Cary, NC). Results: In 40 pts who met criteria, 9 (22.5%) underwent curative intent resection/ ablation, 34 (85%) had recurrent or de novo locally advanced or metastatic stage and of them 33 (82.5%) received any therapy for advanced cancer. Of these 33 pts, 25 (75.7%) were female, 29 (87.9%) non-Hispanic White and 32 (97%) had intrahepatic subtype with a median (range) age of 65 (28-82) years. NGS on tissue (51.5%), plasma (21.2%) or both tissue and plasma (27.3%) identified IDH2 R172* in 28 (84.8%), I98T in 1 (3%), F278fs in 1 (3%) pts and not reported/missing in 1 (3%) pt. Most common co-altered genes included TP53 (27.5%), ARID1A (17.5%), PBRM1 (12.5%), CDKN2A (10%), BAP1 (10%). FGFR2 fusion or N/KRAS mutation was present in 2 (5%) pts each. Of 33 pts with advanced stage, 1L therapy was gemcitabine/platinum +/- devimistat or durvalumab in 84.9%. Median (95% CI) progression-free survival (PFS) on 1L chemotherapy and overall survival were 6.6 (4.1-7.8) and 16.3 (12.1-28.9) months, respectively. Eight of 33 (24.2%) pts with advanced stage received off label enasidenib as Nth line therapy with median PFS (95% CI) 3.9 (1.1-5.1) months. Conclusions: Most pts with IDH2 mutation had advanced ds with median survival similar to those with IDH1 mutated advanced cholangiocarcinoma. Off label enasidenib had modest benefit in this rare subset of pts and should be investigated further.
Single-arm phase 2 study of the FGFR inhibitor futibatinib (Futi) in combination with pembrolizumab (Pem) in patients with FGF19 expressing advanced or metastatic hepatocellular carcinoma (aHCC).
Palmer, Mathias Earl, Ulrich, Angela, Babiker, Hani M., Revzin, Alexander , Gores, Gregory J., Jin, Zhaohui, Fonkoua, Lionel Aurelien Kankeu, Roberts, Lewis R. , Goenka, Ajit H. , Mahipal, A., Tran, Nguyen H., Roberts, Lewis R , Wee, Wen , Bekaii‐Saab, Tanios , Borad, Mitesh J. , Babiker, Hani M. , Majeed, Umair , Gores, Gregory J. , Hálfdánarson, Þorvarður R. , Jin, Zhaohui , Fonkoua, Lionel Aurelien Kankeu , McWilliams, Robert R. , Graham, Rondell P. , Heimbach, Julie K. , Mahipal, Amit , Ou, Fang‐Shu , Tran, Nguyen H.

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 561-561

10.1200/jco.2026.44.2_suppl.561 Get It

561 Background: For patients with aHCC, second-line treatment options are not well established. The primary aim of this study was to evaluate the efficacy of Futi, an FGFR 1-4 inhibitor, in combination with Pem as a second line therapy in patients with FGF19-expressing aHCC. Methods: Patients aged ≥ 18 years, with histological/cytological diagnosis or radiological diagnosis of HCC, Child-Pugh (CP) class A-B7, Barcelona Clinic Liver Cancer (BCLC) A, B or C, ECOG performance status of 0-2, and FGF19+, by in-situ hybridization or immunohistochemistry, received Futi 20 mg once daily plus i.v. Pem 200mg every 3 weeks. The primary endpoint was progression-free survival at 6 months (PFS6). Secondary endpoints include overall survival (OS). The study was designed to enroll 22 evaluable patients to detect PFS6 from 25% (historical control) to 47%, assuming a 1-sided alpha of 0.1 with 80% power. All patients provided written consent. Eligible patients with consent who started treatment are considered evaluable. Results: The study was closed to enrollment early at the request of funding agency due to poor accrual. Between 8/2021 and 3/2024, 14 patients enrolled with 1 patient withdrawing consent before beginning protocol treatment. Among 13 evaluable patients, median age was 72 (range: 60-87) years, 7 (53.8%) were male, 12 CP A (92.3%), 7 BCLC C (53.8%), with 7 (53.8%) having received prior liver directed therapy. Median PFS was 15 weeks (95% confidence interval [CI]: 9.0-Not Estimable) and PFS6 was 23.1% (95% CI: 8.6%, 62.3%). Objective response rate was 0% (95% CI: 0%, 24.71%) and stable disease occurred in 7 (53.9%) of patients. Median OS was 55.7 weeks (95% CI: 47.3-NE). Nine (69.2%) patients experienced at least 1 grade 3+ adverse event (AE), and 2 (15.4%) patients experienced at least a grade 4+ AE. One patient had a grade 5 AE unrelated to study treatment (acute kidney injury). Most commonly reported AEs (occurring in more than 31% of patients) were hyperphosphatemia (76.9%), fatigue (69.3%), diarrhea (61.6%), AST (53.9%) and ALT (46.2%), dry eye (38.5%), nail changes (38.5%), rash-maculo-papular (38.5%), and mucositis oral (38.5%). Conclusions: This prospective study evaluated the use of a targeted treatment in combination with immunotherapy following first line immune-based therapy. This combination had modest activity as a second line therapy for patients with aHCC but did not meet the primary endpoint. The safety profile was acceptable and consistent with prior reports. An optimal second-line regimen remains a critical need. Clinical trial information: NCT04828486 .